Navigation path



The Second Phase of a European Malaria Vaccine Development Consortium
Framework programme:
Project number:
EC contribution:
€ 3 700 044
36 months
Starting date:
1 September 2002


The EUROMALVAC2 consortium will develop malaria vaccines inducing protective antibody responses to Plasmodium falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating second and third generation candidates in its malaria vaccine R&D 'pipeline '. The major projects within the EUROMALVAC2 work programme involve: a) an optimisation of synthesis of lead candidate malaria vaccines based on merozoite surface protein 1 (MSPl ) and the apical merozoite antigen 1 (AMAl ); b) production and testing of more parasitised erythrocyte membrane protein (PfEMP-l)-based vaccines; c) production and testing of new vaccine formulations based on the N-terminal Block 2 sequences of MSP1 and on other, less well characterised merozoite antigens; d) development of a transmission blocking vaccine based on gametocyte antigen Pfs48/45; e) strengthening of preclinical and clinical testing facilities.


EUROMALVAC1 has brought PfMSP119 and PfAMA1 vaccines close to clinical trial and has developed an experimental PfEMP1 vaccine. More second generation vaccines are now needed for clinical trials and accelerated development of an effective malaria vaccine. EUROMALVAC2's plan is to expand Europe's portfolio of vaccines inducing protective antibody responses to key malaria antigens, continuing to validate vaccine constructs in the pipeline while optimising the lead vaccines in preparation for their phase I trials. More 'first' generation PfEMP1 vaccines will be tested, as will a novel MSP1 Block 2 vaccine. Development and validation studies will be initiated for MSP 3-8 and a prototype transmission blocking vaccine will be made. Further development of pre-clinical and clinical trial facilities will be carried out.

[+] Read More